Complexes of Ni(II) and Cu(II) with ofloxacinCrystal structure of a new Cu(II) ofloxacin complex

Macı́as, Benigno; Villa, M.; Rubio, Inmaculada; Castiñeiras, Alfonso; Borrás, Joaquı́n

doi:10.1016/s0162-0134(01)00182-9

Cited by 128 publications

(63 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The structure of a metal complex of silver with OFL has not been published yet. By association with patterns obtained so far using OFL, in this study, it is possible to obtain a compound with a stoichiometric metal: ligand of 1:2 or 1:1 while ratio of 1:3 is unlikely [13][14][15][16][17][18][19][20][21]27]. In the mass spectrum (m/z 830.9) is highlighted the molecular ion Ag(OFL) 2 + , corresponding to ratio metal:ligand of 1:2 combination, and m/z 362.1 corresponding to the molecular ion of the free OFL.…”

Section: Ms Spectra Analysismentioning

confidence: 71%

“…Due to the specific complexation ability of fluoroquinolones, in the case of OFL several metalic complexes (Mg 2+ , Ca 2+ , Ba 2+ , Ni 2+ , Zn 2+ , Cu 2+ , Co 2+ , Pd 2+ , Pt 2+ , Bi 3+ ) have been studied before in terms of antimicrobial activity (including Helicobacter pylori and Mycobacterium tuberculosis), binding to DNA and to albumins [13][14][15][16][17][18][19][20][21]. At the moment only a few metal complexes with silver of antibacterial quinolones are known: nalidixic acid, pipemidic acid (first generation), pefloxacin, norfloxacin, ciprofloxacin (second generation), moxifloxacin (fourth generation) [5,6,11,[22][23][24].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A New Silver Complex with Ofloxacin – Preliminary Study

Rusu

Popescu

Imre

et al. 2016

Acta Medica Marisiensis

View full text Add to dashboard Cite

Objective: Silver complexes of antibacterial quinolones have the potential advantage of combining the antibacterial activity of silver and fluoroquinolones. The objective of our study was the preparation and the preliminary physico-chemical characterization of a silver complex with ofloxacin. Methods: To achieve our goals several spectroscopic methods (ultraviolet spectrophotometry, mass spectrometry, and Fourier transform infrared spectroscopy) and thermal methods (differential scanning calorimetry and thermogravimetric analysis) were used in order to elucidate the chemical structure of the complex. Results: Using mass spectrometry we established the stoichiometric ratio silver:ofloxacin as 1:2. Experimental data suggest a particular coordination for ofloxacin, as a monodentate ligand, in the formation of a complex with silver, through the nitrogen atom from the methyl-piperazine cycle. IntroductionDue to the excellent chelating properties of quinolone antibacterial several metal complexes of these substances were synthesized and studied for their possible antibacterial and antifungal activities. The silver ion is known for its antibacterial and antifungal properties. Fluoroquinolones are synthetic antibacterial agents, with broad spectrum activity, good oral absorption and bioavailability. The 4-oxo and 3-carboxyl groups of fluoroquinolones offer excellent chelating properties for metal ions. Silver complexes of fluoroquinolone antibacterial have the advantage of combining the antibacterial activity of the silver ion with the one of the fluoroquinolone. There are a large number of studies on the complexation of antibacterial fluoroquinolones with metal ions using different metals [1]. Metal complexes have been synthesized with antimicrobial activity equal to or greater with the corresponding quinolone antibacterial. Research on the fluoroquinolone metal complexes has revealed also other biological effects: antifungal, antiparasitic, anticancer, anti-inflammatory, antioxidant and even insulin mimetic [2][3][4]. In the category of metal complexes with promising therapeutic effects are included those containing silver [5][6][7][8][9][10].Complexation of antibacterial quinolones with silver combines the antibacterial activity of Ag (I) with the one of the quinolone. This complexation presents a particular coordination with the quinolone as the monodentate ligand

show abstract

Section: Ms Spectra Analysismentioning

confidence: 71%

Section: Introductionmentioning

confidence: 99%

A New Silver Complex with Ofloxacin – Preliminary Study

Rusu

Popescu

Imre

et al. 2016

Acta Medica Marisiensis

View full text Add to dashboard Cite

show abstract

“…A literatura reporta complexos com ciprofloxacina, [74][75][76][77][78] esparfloxacina, 79 cinoxacina, [80][81][82] ácido nalidíxico 83 e norfloxacina. [84][85][86] Complexos de cobre contendo a esparfloxacina e ligantes nitrogenados foram recentemente relatados 87 e estão entre os mais ativos contra Escherichia coli, Pseudomonas aeruginosa e Staphylococcus aureus, quando comparados com outros complexos de cobre contendo …”

Section: Coordenação De Metais a Quinolonas E Fluorquinolonasunclassified

Coordenação de metais a antibióticos como uma estratégia de combate à resistência bacteriana

Rocha¹,

Pinto²,

Ruggiero³

et al. 2011

Quím. Nova

View full text Add to dashboard Cite

Recebido em 12/1/10; aceito em 2/8/10; publicado na web em 16/11/10 COORDINATION OF METALS TO ANTIBIOTICS AS A STRATEGY TO COMBAT BACTERIAL RESISTANCE. Antibiotic resistance has been growing at an alarming rate and consequently the arsenal of effective antibiotics against Gram-negative and Gram-positive bacteria has dropped dramatically. In this sense there is a strong need to produce new substances that not only have good spectrum of activity, but having new mechanisms of action. In this regard, this paper emphasizes the coordination of metals to antibiotics as a strategy for reversing antibiotic resistance and production of new drugs, with a special focus on quinolones, fluoroquinolones, sulfonamides and tetracyclines.Keywords: antibiotics; metal-based drugs; bacterial resistance. INTRODUÇÃOA descoberta dos antibióticos representa um dos mais importantes marcos da medicina moderna. A introdução das sulfonamidas em 1930 e da penicilina na década posterior provocaram um grande avanço no tratamento de doenças infecciosas, causando uma drásti-ca diminuição nas taxas de mortalidade e uma enorme sensação de bem-estar. 1 O sucesso dos primeiros antibióticos na cura de doenças até então consideradas letais acarretou uma intensa busca por novas drogas. De fato, as décadas de 40, 50 e 60 do século passado foram marcadas pela imensa quantidade de antibióticos produzidos e rapidamente incorporados às práticas clínicas. 2 No entanto, nas décadas posteriores houve um declínio na produção destes compostos. Entre o lançamento das quinolonas em 1962 até a aprovação das oxazolidinonas em 2000, houve pouca inovação no que se refere à introdução de novas classes de antibióticos de uso clínico bem-sucedido. 2 Quando um antibiótico é descoberto e introduzido no mercado, sua utilidade clínica começa a diminuir até um ponto em que há um aumento na restrição de seu uso. Esta restrição é provocada pelo surgimento de cepas resistentes. As bactérias surgiram na terra há bilhões de anos e para sobreviver desenvolveram mecanismos de resistência aos antibióticos que são encontrados livres na natureza. 3 Portanto, não é surpreendente o fato de que muitos antibióticos lançados nas últimas décadas, que são em sua ampla maioria de origem natural ou semissintética, terem utilidade limitada na época de sua descoberta e em pouco tempo se tornarem obsoletos. 3 Outro fator que contribui muito para tornar um antibiótico menos eficiente é a sua utilização indiscriminada e incorreta, o que vem a favorecer o surgimento de micro-organismos resistentes. Atualmente, algumas classes de micro-organismos representam extrema preocupação para a saúde publica. Dentre os que mais provocam mortes no mundo estão o Staphylococcus aureus meticilina-resistente (MRSA), Staphylococcus aureus vancomicina-resistente (VRSA), Escherichia coli, Klebsiella pneumoniae e Pseudomonas aeruginosa, que são bactérias resistentes a múltiplas drogas. Os processos infecciosos causados por estas classes de micro-organismos geralmente estão associados com alta letalidade e altos custos d...

show abstract

“…Ofloxacin interacted directly with Sm(III) salt in an aqueous medium at natural pH, however, the compound formed in such a way, could not be well defined from a chemical point of view, as the anion of original metal salt was usually incorporated to the compounds formed, giving rising to formation of polymers [9]. To avoid such a polymers formation, the reaction was carried out in an acidic medium as follows: 0.2 g Sm 2 O 3 dissolved in proper 1 M HCl at 60 • C, and 0.42 g ofloxacin dissolved in 5 ml 1 M HCl in another beaker at 60 • C, after a few minutes, mixed two solutions together, stirring thoroughly.…”

Section: Synthesis Of the Complexmentioning

confidence: 99%

Structural characterization and DNA-binding properties of Sm(III) complex with ofloxacin using spectroscopic methods

Chen

Long

et al. 2009

Spectroscopy

View full text Add to dashboard Cite

Abstract.A novel complex Sm(III) complex with ofloxacin was synthesized and characterized on the basis of elemental analyses, molar conductivities, IR spectra, thermal analysis (TG-DSC), 1 H-NMR spectra. Then, spectrometric titration, ethdium bromide displacement experiments by UV spectroscopy, ionic influence, viscosity measurements and Circular Dichroism (CD) spectroscopic measurements were conducted to characterize the interaction between the complex and CT-DNA. Results obtained indicate that the complex bound with CT-DNA via an intercalation mechanism. The binding constants and binding sites number of the Sm(III) complex with CT-DNA were 1.80 × 10 5 l·mol −1 and 1, respectively.

show abstract

Complexes of Ni(II) and Cu(II) with ofloxacinCrystal structure of a new Cu(II) ofloxacin complex

Cited by 128 publications

References 11 publications

A New Silver Complex with Ofloxacin – Preliminary Study

A New Silver Complex with Ofloxacin – Preliminary Study

Coordenação de metais a antibióticos como uma estratégia de combate à resistência bacteriana

Structural characterization and DNA-binding properties of Sm(III) complex with ofloxacin using spectroscopic methods

Contact Info

Product

Resources

About